Traboulsee A, et al. - In the current study, the effectiveness of interferon beta-1a given subcutaneously (IFN β-1a SC) three times weekly (tiw) vs placebo on clinical and radiological endpoints, including no evidence of disease activity (NEDA), was described. The impact of IFN β-1a SC in prespecified patient subgroups was also assessed. Researchers reported that IFN β-1a SC tiw treatment had significant early benefits on clinical and radiological endpoints. In addition, effectiveness was confirmed using varying definitions of NEDA. They observed that the effectiveness of IFN β-1a SC tiw across patient subgroups was consistent with effects seen in the overall treatment population.